Of Hong Kong and Macao Drugs and Medical Devices Urgently Needed in Clinical Practice in the Nine Mainland Cities of the GuangdongHong KongMacao Greater Bay Area of Guangdong Province issued by the Guangdong Provincial Drug Administration and the Guangdong Provincial Health Commission in December, which will accelerate its implementation in the 45 medical institutions designated by the "Hong Kong and Macao Drug and Medical Device Access".
Luo Yongqing, CEO of Everest Medicines, said: "I am very pleased to see new zealand mobile number list that the New Drug Marketing Authorization Application for Itramod has been officially accepted in mainland China. Following Macau, China and Singapore, Itramod is expected to be the third region approved within Everest Medicines' authorized territory. There is a huge unmet need for innovative therapies for patients with ulcerative colitis in China. By 2030, the number of patients in China is expected to reach approximately 1 million, more than double the number of patients in 2019. We will continue to work hard to expand the accessibility of Itramod and look forward to benefiting more patients with ulcerative colitis.